CoChat

Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer’s Disease and Other Neurodegenerative Diseases

Calsolaro, Valeria, Edison, Paul · 2015 · CNS Drugs

The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.

Abstract

The link between diabetes mellitus and Alzheimer's disease (AD) has been known for the last few decades. Since insulin and insulin receptors are known to be present in the brain, the downstream signalling as well as the effect of hyperinsulinemia have been extensively studied in both AD and Parkinson's disease. Glucagon-like peptide-1 (GLP-1) is a hormone belonging to the incretin family, and its receptors (GLP-1Rs) can be found in pancreatic cells and in vascular endothelium. Interestingly, GLP-1Rs are found in the neuronal cell body and dendrites in the central nervous system (CNS), in particular in the hypothalamus, hippocampus, cerebral cortex and olfactory bulb. Several studies have shown the importance of both insulin and GLP-1 signalling on cognitive function, and many preclinical studies have been performed to evaluate the potential protective role of GLP-1 on the brain. Here we review the underlying mechanism of insulin and GLP-1 signalling in the CNS, as well as the preclinical data for the use of GLP-1 analogues such as liraglutide, exenatide and lixisenatide in neurodegenerative diseases.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40263-015-0301-8

Cites

107 of 107 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 107 references

Cited by

See all 93

Metadata

Authors
Calsolaro, V., & Edison, P.
Affiliations
Hammersmith Hospital (GB)
Corresponding author
Edison, Paul
Venue
CNS Drugs
Published
2015-12
Volume
29
Issue
12
Pages
1023-1039
ISSN
  • 1172-7047 (ISSN-L)
  • 1179-1934
OpenAlex
W2221406620
Cited by
93
References
107
Citations by year
2026: 3 · 2025: 8 · 2024: 10 · 2023: 9 · 2022: 12 · 2021: 7 · 2020: 8 · 2019: 11 · 2018: 9 · 2017: 12 · 2016: 4
FWCI
1.02
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Alzheimer's Drug Discovery Foundation (US)
  • Alzheimer’s Research UK (GB)
  • Alzheimer's Society (GB)
  • Van Geest Foundation
  • Medical Research council, UK
  • Novo Nordisk (DK)
  • GE Healthcare (GB)
  • Piramal Life Science
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
glucagon-like peptide-1, GLP-1 receptor, GLP-1 analogues, insulin signaling, Alzheimer's disease, Parkinson's disease, neurodegenerative diseases, diabetes mellitus, liraglutide, exenatide, lixisenatide, cognitive function, preclinical drug development
MeSH terms
Alzheimer Disease, Animals, Humans, Insulin, Neuroprotective Agents, Neurodegenerative Diseases, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer’s Disease and Other Neurodegenerative Diseases. https://app.cochat.ai/papers/10.1007/s40263-015-0301-8
The paper
Calsolaro, V., & Edison, P. (2015). Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer’s Disease and Other Neurodegenerative Diseases. CNS Drugs. https://doi.org/10.1007/s40263-015-0301-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.